As of November 7, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Lineage Cell Therapeutics Inc. The largest reported stake is Broadwood Partners, L.P.'s, at 23.1%. 4 filings are on record since July 17, 2025 (Schedule 13D/A, November 14, 2025).
Sell to companies like Lineage Cell Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 13,024,110 · Shared voting: 0 · Sole dispositive: 13,185,489 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
- · Holder: Broadwood Partners, L.P. · Percent: 23.1% · SCHEDULE 13D/A
- · Holder: Chernett Jorey · Percent: 5% · SCHEDULE 13G
- · Holder: BlackRock, Inc. · Percent: 1% · SCHEDULE 13G/A
Lineage Cell Therapeutics Inc has 4 Schedule 13D or 13G filings on record since 2025-07-17. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Broadwood Partners, L.P. | 23.1% | 57,455,729 | SCHEDULE 13D/A, 2025-11-14 | 2025-11-12 |
| BlackRock, Inc. | 5.3% | 13,185,489 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| 5% | 11,445,003 | SCHEDULE 13G, 2025-09-26 | 2025-09-22 |
Holding shares or following this stake? See who's behind Lineage Cell Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Lineage Cell Therapeutics Inc and the records around it.
Lineage Cell Therapeutics Inc elsewhere on the record
Companies that share a holder
- BROADWOOD PARTNERS, L.P. also filed stake reports on 2 other companies: Insight Molecular Diagnostics Inc. (Apr 2026), STAAR SURGICAL CO (Mar 2026)
- Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Lineage Cell Therapeutics Inc
Get an email when Lineage Cell Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lineage Cell Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lineage Cell Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lineage Cell Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,024,110 | 0 | 13,185,489 | 0 | SCHEDULE 13G, 2026-07-29 |
The latest filing identifies Lineage Cell Therapeutics Inc by CUSIP 53566P109 and gives its principal executive office as 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA 92008 (SCHEDULE 13G, 2026-07-29).
Purpose of Transaction (Item 4)
Broadwood Partners, L.P.
The Reporting Persons acquired their Shares for investment and are filing this Schedule 13D/A to report a decrease in their respective beneficial ownership percentages of the Shares as a result of the sale of 12,000,000 Shares by the Issuer to Janus Henderson Investors in a block transaction under the Issuer's at-the-market offering program as described in the Form 8-K filed with the Securities and Exchange Commission by the Issuer on November 12, 2025 (the "Form 8-K"). The foregoing is a summary of certain material terms of the Form 8-K. However, such summary is not, and does not purport to be, complete and is qualified in its entirety by reference to the full text of the Form 8-K, which has been filed as Exhibit B, and is incorporated herein by reference. Mr. Bradsher serves on the Board of Directors. Except as otherwise set forth below, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D. However, subject to market conditions and in compliance with applicable securities laws, the Reporting Persons reserve the right, at a later date, to effect one or more of such changes or transactions in the number of Shares they may be deemed to beneficially own in open-market or privately negotiated transactions, on such terms and at such times as the Reporting Persons may deem advisable. The Reporting Persons have been and may continue to be in contact …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 1% | SCHEDULE 13G/A |
| 2025-09-26 | Chernett Jorey | 5% | SCHEDULE 13G |
| 2025-11-14 | Broadwood Partners, L.P. | 23.1% | SCHEDULE 13D/A |
| 2026-07-29 | BlackRock, Inc. | 5.3% | SCHEDULE 13G |
Questions about who owns Lineage Cell Therapeutics Inc
Who owns Lineage Cell Therapeutics Inc?
On this page, 3 holders' latest ownership filings report 5% or more of Lineage Cell Therapeutics Inc: Broadwood Partners, L.P. (23.1%, Schedule 13D/A, filed 2025-11-14), BlackRock, Inc. (5.3%, Schedule 13G, filed 2026-07-29) and Chernett Jorey (5%, Schedule 13G, filed 2025-09-26).
Who are the largest shareholders of Lineage Cell Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Lineage Cell Therapeutics Inc on this page are Broadwood Partners, L.P. (23.1%), BlackRock, Inc. (5.3%) and Chernett Jorey (5%).
When did Broadwood Partners, L.P. buy into Lineage Cell Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Broadwood Partners, L.P. on this page is the Schedule 13D/A, filed 2025-11-14, reporting 23.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Lineage Cell Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.